Genetic Makeup Sways Medication Choices for 25% of Patients: Study

One critical aspect your physician might overlook when recommending medications is your genetic makeup.

A recent study released on Wednesday in Science Translational Medicine revealed that almost 25% of the participants had been prescribed a medication that might have necessitated a different drug or dosage based on their genetic profile.

This research, conducted by scientists at the University of Pittsburgh, focused on 16 genes that influence the body’s reaction to various medications.

DNA samples from 98,590 individuals involved in the National Institutes of Health’s All of Us Research Program were analyzed and correlated with participants’ medical histories when available.

Every participant carried at least one pertinent genetic variation that could influence their response to specific medications, with the average individual carrying nine. Among those with both genetic and clinical data, 24.4% had been prescribed a medication that, according to genetic guidelines, should have been substituted with an alternative drug or adjusted in dosage.

Nevertheless, the study did not ascertain whether patients suffered from side effects or if the efficacy of their medications was diminished due to their genetic factors.

Dr. Philip Empey, the senior author and an associate professor at the University of Pittsburgh’s School of Pharmacy, emphasizes that understanding a patient’s genetic data could minimize the trial-and-error approach often seen in medicine.

“Anything we can do to enhance our predictions about the optimal medications and dosages from the outset can significantly reduce that trial and error,” he stated.

A woman in a medical mask sorts pills on a counter.

A pharmacist organizes medications at a Vancouver pharmacy in October 2022. Genetic differences can influence how patients react to specific drugs, possibly requiring doctors to modify dosages or prescribe alternate medications. (Darryl Dyck/The Canadian Press)

Identifying the appropriate medication

Among the most frequently prescribed medications to participants whose genetic profiles could suggest necessary treatment adjustments were omeprazole and pantoprazole for acid reflux, along with atorvastatin for cholesterol management.

Empey notes that certain genetic variations may heighten the likelihood of muscle complications when individuals take statins like atorvastatin, which are utilized to minimize heart attack or stroke risks.

This understanding could guide physicians in selecting an alternative medication or modifying treatment strategies.

“This enables clinicians to make more informed choices, such as considering, ‘Perhaps not that cholesterol medication. Maybe we should initiate treatment more cautiously. Perhaps we need to set a maximum dosage or monitor specific toxicities more closely,'” Empey explained.

In some cases, the implications can be more severe.

Experts consulted by CBC News indicate that genetic testing can help pinpoint patients who are unlikely to respond effectively to clopidogrel (Plavix), a medication prescribed to prevent blood clots after cardiac stenting, allowing healthcare providers to switch them to a different drug.

A man in a suit and tie sits in a laboratory.

Dr. James Kennedy leads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health. He asserts that while genetic testing can aid in medication selection, other factors, such as diet, lifestyle, and existing medications, must also be taken into account. (CBC)

A framework, not a certainty

Dr. James Kennedy, who heads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health (CAMH), remarked that the findings of the study were expected, particularly due to the genetic diversity and representation of individuals of African descent.

Kennedy’s team has conducted genetic testing for around 11,000 patients, many of whom had already tried multiple antidepressants without satisfactory outcomes.

He mentions that roughly 8% to 10% of individuals metabolize certain commonly prescribed antidepressants at an unusually slow rate, leading to potential drug accumulation and side effects.

According to Kennedy, genetic testing is particularly advantageous for patients who have previously faced challenges with various medications.

However, he stresses that DNA testing alone cannot fully predict how a patient will respond to a specific medication. Other factors, including concurrent medications, smoking habits, and dietary choices, must also be factored in.

“We provide a framework, highlighting any tendencies, and then discuss all other considerations necessary before making a conclusive decision,” he elaborated.

A 2023 European clinical trial referenced in the study indicated that conducting genetic testing prior to prescribing certain medications reduced adverse drug reactions. However, implementing such testing as a standard practice in Canada presents challenges.

A person in purple gloves points to a small plastic test tube.

A researcher from the University of Calgary shows a diagnostic kit used for identifying genetic variations in February 2024. Although such testing could assist doctors in customizing medications for individual patients, costs and practical challenges have hindered its broader application in Canada. (Jeff McIntosh/The Canadian Press)

Challenges of universal testing in Canada

Dr. Jacob Udell, a cardiologist in Toronto, praised the study for its impressive genetic diversity among participants, but noted that few healthcare providers in Canada or the U.S. routinely assess patients for genetic variations that may influence their medication metabolism.

“It’s not typically on the radar for frontline clinicians,” he stated.

Udell pointed out that for many medical conditions, physicians can prescribe a treatment, observe how the patient responds, and make necessary adjustments without facing severe repercussions. This method can be more practical than routinely screening for genetic variations.

He also questioned whether widespread genetic testing should be prioritized given the current difficulties within Canada’s healthcare system to provide fundamental services.

“We are primarily focused on ensuring everyone has access to a family physician,” he commented.

Aside from the expense of genetic tests, Udell mentioned that clinicians would need access to test results and the capability to interpret them accurately.

Empey concurred that establishing routine genetic testing would necessitate a substantial investment in training, infrastructure, and systems to facilitate the sharing of results among healthcare providers.

“The scientific backing is robust for various medications. The implementation challenges, however, are more related to economic considerations, procedural aspects, and educational needs,” he noted.

Currently, Empey recommends that patients inquire with their doctors or pharmacists about the potential benefits of genetic testing and share any relevant results.

Udell cautioned that private genetic testing might become more prevalent for those who can afford it, “but this won’t assist those who cannot pay for the testing.”